



## **Senzime reports from the American Society of Anesthesiologists (ASA) Annual Meeting in San Francisco, CA, USA**

**News: Uppsala, 17 October 2018.**

For more than 68 years, the ASA Annual Meeting has been the most comprehensive anesthesia-related educational event in the world, bringing together top influential and notable professionals in anesthesiology, pain medicine and critical care medicine.

Numerous presenters discussed patient safety initiatives and necessary steps to reduce adverse events in the perioperative period. Hundreds of technical, scientific and educational exhibits displaying and demonstrating the latest products, services and industry research.

During the exhibition Senzime had the opportunity to address a worldwide audience of Key opinion leaders and demonstrate the TetraGraph, as well as formally launch the TetraGraph Viewer. This software allows the user to easily export patient data.

*“The anesthesia discussions today is all about having the patient in focus. The ability to digitally present data and analyze trends is a key component,”* says Lena Söderström, CEO of Senzime.

Senzime's distributors from Australia & New Zealand and South Korea also attended the event to meet with local customers visiting the conference.

### **For further information, please contact:**

Lena Söderström, CEO

Tel: +46-708 16 39 12. Email: [lena.soderstrom@senzime.com](mailto:lena.soderstrom@senzime.com)

### **TO THE EDITORS**

#### **About Senzime**

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients' neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. [www.senzime.com](http://www.senzime.com)